Targeted modified TNF family members

US11396532B2 · kind B2 · utility

Assignees

• VIB VZW · BE
• UNIVERSITEIT GENT · BE
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
• Universite De Montpellier · FR
• Centre Hospitalier Regional Universitaire de Montpellier · FR

Inventors

• Jan Tavernier · Balegem, BE
• Jennyfer Bultinck · Ledeberg, BE
• Frank Peelman · Gentbrugge, BE
• Gilles Uze · Montpellier, FR

Key dates

• Filing date: May 4, 2020
• Grant date: Jul 26, 2022
• Expiry date: Jun 25, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/74
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains can-y one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.